key: cord-0886584-8sg45zns authors: Min, Kyung-Jin; Suh, Dong Hoon; Baba, Tsukasa; Chen, Xiaojun; Kim, Jae-Weon; Kobayashi, Yusuke; Kwon, Janice; Lim, Myong Cheol; Lee, Jung-Yun; Nagase, Satoru; Park, Jeong-Yeol; Tangjitgamol, Siriwan; Watari, Hidemichi title: Time for enhancing government-led primary prevention of cervical cancer date: 2020-12-11 journal: J Gynecol Oncol DOI: 10.3802/jgo.2021.32.e12 sha: df39b82ecdd050b2829863b3a70d3b284f1d5002 doc_id: 886584 cord_uid: 8sg45zns nan Jung-Yun Lee https://orcid.org/0000-0001-7948-1350 Satoru Nagase https://orcid.org/0000-0001-5212-1128 Jeong-Yeol Park https://orcid.org/0000-0003-2475-7123 Siriwan Tangjitgamol https://orcid.org/0000-0001-5367-8884 Hidemichi Watari https://orcid.org/0000-0002-4189-6187 No potential conflict of interest relevant to this article was reported. 2020, pending the announcement of national HPV vaccination coverage. In India, several local governments started HPV vaccination programs after vaccines were made available in 2008 [6] . HPV vaccination was suspended after several deaths occurred during these initial programs. However, local governments, including Punjab and Delhi, resumed sponsoring their HPV vaccine programs. A recent study for 11-year-old girls in Punjab state found that HPV vaccination appeared highly cost-effective, suggesting a rationale of implementing HPV vaccination as a NIP in India [7] . Nevertheless, their national coverage is still low. In China, recent rates of both HPV vaccination and cervical cancer screening remain low [8] . According to a recent study conducted on Chinese college students [9] , only 3.1% of the study group had been vaccinated and 36.9% of women were willing to be vaccinated. To overcome this situation, the Chinese government included a HPV vaccination program within national basic public health services in 2019. However, there was no national HPV vaccination program in China as of August 2020. Very low coverage of HPV vaccination below 1% in Japan seems mainly due to the anti-vaccine movement, which excessively claims rare adverse events such as complex regional pain syndrome, despite the absolute benefit [10, 11] . Japan had a NIP which was then suspended in 2013. The Japanese government has estimated that 67,305 deaths would be attributed to cervical cancer in Japan over the next 20 years without resuming the NIP [11] . In Korea, the NIP began in 2016, which provides HPV vaccination for girls at the age of 12 years. HPV vaccine coverage is high only for the specific birth cohorts which are covered by NIP: 86.3% for 2007 births and 47.2% for 2008 births [12] . Since HPV vaccines were introduced in Korea in 2006, the incidence of cervical cancer has been slowly decreasing for the last 15 years. However, vaccine coverage in all age groups was estimated around 26% [13] . The absence of a steeper decline of cervical cancer incidence (Fig. 2) [14] , which was expected through herd immunity, is probably because of this low vaccine coverage in Korea. WHO recently launched the strategy to eliminate cervical cancer with the goals of achieving 90% HPV vaccination coverage, 70% screening coverage, and 90% access to treatment for cervical pre-cancer and cancer [2] . Many relevant societies worldwide including the Korean Society of Gynecologic Oncology have been scrambling to release their own recommendations for HPV vaccines [15] [16] [17] [18] . Despite these consistent efforts of WHO and various academic societies, the HPV vaccination strategies of governments in Japan and Korea do not seem satisfactory. There was no policy change of HPV vaccination program in Japan, and the NIP has remained suspended since 2013 [11] . There was no further advancement of NIP after its commencement in 2016 in Korea. Both countries have demonstrated the capacity for efficient resource allocation in the midst of the COVID-19 pandemic. However, with respect to allocating resources for HPV-related disease prevention, the health-related departments of both countries have failed. Based on the solid scientific evidence of the benefits of the HPV vaccine [1] , the governing bodies should respond actively to step up, restarting the HPV vaccination program, improving current coverage by extending the age groups and incorporating nonavalent vaccines into NIP, and promoting the benefits of HPV vaccination which include reduction in morbidity and mortality as well as costs incurred from treating cervical cancer. Establishing an appropriate outcome-measuring system including a national registry for HPV vaccination is also an essential element to effectively save lives threatened by this preventable disease [19] . [Access December 10, 2020]. Incidence (B) and crude incidence rate (C) of cervical cancer in Korea [14] . HPV vaccination and the risk of invasive cervical cancer Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators Cervical cancer in Australia statistics World Health Organization, The Global Health Observatory. Girls aged 15 years old that received the recommended doses of HPV vaccine Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis Human papillomavirus vaccination: coverage rate, knowledge, acceptance, and associated factors in college students in mainland China Epidemiologic profile of typespecific human papillomavirus infection after initiation of HPV vaccination Two viral infections in Japan Korean Disease Control and Prevention Agency. National Immunization Program Guide Osong: Korean Disease Control and Prevention Agency; c2020 Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study Statistical Database: Cancer incident cases and incidence rates by site (24 items), sex, age group Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices Human papillomavirus vaccination: the ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy EBCOG position statement: gender neutral HPV vaccination for young adults Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a National Immunization Program We would like to thank Dr. Sudeep Gupta (Director ACTREC, Mumbai, India) for providing information of India.